Sinovac Research And Development Co Ltd

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19

Phase 1

Completed

Interventions: Other: Two doses of placebo at the schedule of day 0,28
Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

Locations: 🇨🇳
Zanhuang county Center for Disease Control and Prevention, Shijiazhuang, Hebei, China

Phase 1

Completed

Interventions: Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
Biological: Two doses of placebo at the emergency vaccination schedule
Biological: Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
Biological: Three doses of placebo at the routine vaccination schedule
Biological: Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
Biological: Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
Biological: Two doses of placebo at the routine vaccination schedule
Biological: Three doses of placebo at the emergency vaccination schedule
Biological: Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule

Locations: 🇨🇳
Suining County Center for Disease Control and Prevention, Xuzhou, Jiangsu, China